Trade Summary

9 months ago, Van Naarden Jacob, serving as EVP, Pres, Lilly Oncology at Eli Lilly & Co (LLY), purchased 1,000 shares at $647.36 per share, for a total transaction value of $647,360.00. Following this transaction, Van Naarden Jacob now holds 29,206 shares of LLY.

This purchase represents a 4.00% increase in Van Naarden Jacob's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Wednesday, August 13, 2025 and publicly disclosed via SEC Form 4 filing on Wednesday, August 13, 2025 at 12:15 PM ET, meaning the disclosure happened on the same day as the trade.

Eli Lilly & Co operates in the HEALTHCARE sector, specifically within the DRUG MANUFACTURERS - GENERAL industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.